Rajni Kannan on Risk Factors for Melanoma

At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

The FDA has approved a liver-directed therapy to treat metastatic uveal melanoma with hepatic metastases.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

The FDA has launched a priority review of lifileucel based on data from the phase 2 C-144-01 trial.

What are the implications of new approvals for oncology nurses specializing in melanoma?